Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Protara Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Protara Therapeutics, Inc.

TARA

Protara Therapeutics, Inc.

About Protara Therapeutics, Inc.

Protara Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare diseases. Its portfolio includes TARA-002, an immunotherapy for bladder cancer and lymphatic malformations, and IV Choline Chloride for patients on parenteral support. The company leverages scientific advancements and strategic collaborations to bring innovative, potentially life-saving treatments to underserved patient populations.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Protara Therapeutics, Inc.

1
1
Protara Therapeutics, Inc. Protara Therapeutics Reports $17.8 Million Net Loss in Q1 2026, Increases R&D Spending

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Protara Therapeutics, Inc. Protara Therapeutics Reports $64.5M Operating Expenses and $57.4M Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Protara Therapeutics, Inc. Protara Therapeutics Reports $13.3 Million Net Loss in Q3 2025, Sees Increased Operating Expenses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Protara Therapeutics, Inc. Protara Therapeutics Reports $14.96 Million Net Loss in Q2 2025, Increased R&D Expenses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Protara Therapeutics, Inc. Protara Therapeutics Reports $11.9 Million Net Loss in Q1 2025, Increases Investment in Clinical Programs

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Protara Therapeutics, Inc. Protara Therapeutics Reports $44.6 Million Net Loss and $170.3 Million Cash Position for 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Protara Therapeutics, Inc. Protara Therapeutics Reports Improved Financial Position, Advances Clinical Trials for Cancer and Rare Disease Treatments

Via official filing (AI summary) | over 1 year ago | 0 comments